Article and Video CATEGORIES
At ASCO 2018, Dr. Melissa Loh presented a study titled: "Chance of Cure in Advanced Cancer: What Do Older Patients Believe and How Are These Beliefs Related to Their Preferences?". This study looked at patients and their beliefs regarding a cure for cancer, specifically in older patients with advanced cancer. Patients who are certain that they could be cured pose unique challenges for physicians and shows a need for clear communication between patients and their physicians regarding the outcome of treatment and quality of life.
Dr. Loh graciously shared with us a summary of her study.
Chance of Cure in Advanced Cancer: What Do Older Patients Believe and How Are These Beliefs Related to Their Preferences?
Kah Poh (Melissa) Loh, MD; Supriya Mohile, MD, MS (University of Rochester Medical Center)
Paul Duberstein, Ph.D. (Rutgers University)
Despite treatment advances in many cancers, stage 4 or metastatic cancers (with the exception of a few) remain incurable. Existing treatments aim to prolong life in this setting but will never be able to take the cancer away and have it never return. Many older adults have other medical problems, are on many medications, and have limitations in daily activities. Therefore, it is important that older adults have a good understanding of their cancer and the goals of treatment when making decisions. We know that many older adults would prefer to maintain their ability to perform daily activities at home, their ability to think, and their quality of life rather than simply living longer.
In this study that we presented at the American Society of Clinical Oncology (ASCO) Palliative and Supportive Care in Oncology, we estimated how many older patients were absolutely certain that their advanced cancer could be cured. We were also interested in the relationship between their trade-off preferences and beliefs about the chance of cure. This was a sub-study of a larger study that looked at whether or not a comprehensive assessment of health in a wide variety of domains would improve communication (Principal Investigator: Supriya Mohile). The domains that were assessed included their functionality, memory and thinking, health status, medications, nutritional status, psychological health, and social support. The study included patients aged ≥70 years with incurable cancer who were considering or receiving any kind of cancer treatment and had an impairment in one of the domains.
We asked patients about their beliefs about the chance of cure using the following question: “What do you believe are the chances that your cancer will go away and never come back with treatment? Options were: 100%, >50%, 50/50, <50%, 0%, or uncertain. The breakdown is shown below; 5.3% of older patients believed with 100% certainty that their advanced cancer will be cured.
We then presented the patients the following statement: “Maintaining my QoL is more important to me than living longer”; 73% agreed, 19% were neutral, and 8% disagreed. What we found was that those who disagreed with this statement were more likely to believe that there was a 100% chance that their cancer will be cured.
Based on this, we think that in order to help older patients with advanced cancer understand their prognosis, it is important that physicians ask about their preferences, values, emotions, and fears.
You can review the abstract from ASCO 2018 here: https://meetinglibrary.asco.org/record/167043/abstract.
We invite you to ask questions and comment in our community forums!
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...
Recent Comments
That's…